MME overexpression

The developed MME+CAF inhibitor IOX2 (a specific prolyl hydroxylase-2 (PHD2) inhibitor), combined with AG (Paclitaxel + Gemcitabine) and anti-PD1 therapy, demonstrated promising antitumor effects, offering a translational strategy for targeting MME in CAFs of pancreatic cancer. The study findings highlighted the significant role of MME+CAF in pancreatic cancer progression by shaping the TME and influencing key pathways. Targeting MME presented a promising strategy to combat the disease, with potential implications for therapeutic interventions aimed at disrupting MME+CAF functions and enhancing the efficacy of pancreatic cancer treatments.

Conclusion In summary, we identified a novel molecular signature related to the CD10 function on stem cell and representative of pre-malignant cells. Altogether, our analyses demonstrate that the CD10-score is linked to cancer evolution and patient survival and may also contribute to identifying efficient therapies in patients in a broad range of cancers.

Furthermore, the defucosylated mouse IgG version of CMab-31 (31-mG-f) exhibits antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and antitumor activities in mouse xenografts of CHO/CD10 cells. These results indicate that 31-mG-f exerts antitumor effects against CD10-expressing tumors and could be valuable as part of an antibody treatment regimen for them.